TABLE 106Comparison of model results with assumptions from Roche model

ModelADA–DMARDsETN–DMARDsIFX–DMARDsRTX–DMARDsABT–DMARDs
BRAM reference34,30038,90036,10021,10038,400
Changing HAQ increase31,90033,50032,00017,20041,500
Changing short-term withdrawal rate23,80025,10027,40020,50026,400
Changing both24,50024,40026,90017,90030,900
Rochea14,60018,00016,2005,30021,500
a

Results for comparisons not involving RTX are inferred from total costs and QALYs reported by Roche (Tables 101105, p. 226–8 of the company submission).

From: 4, Assessment of cost-effectiveness

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.